Opportunities Preloader

Please Wait.....

Report

Osteoarthritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Industry Report I 2022-04-29 I 413 Pages I Global Markets Direct

Osteoarthritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteoarthritis - Drugs In Development, 2022, provides an overview of the Osteoarthritis (Musculoskeletal Disorders) pipeline landscape.

Osteoarthritis (OA) is one of the most common forms of arthritis. It is a chronic condition in which the cartilage breaks down. Symptoms of osteoarthritis include sore or stiff joints, pain that is worse after activity, bone spurs and grating sensation. Risk factors include older age, joint injuries and obesity. Treatment includes surgery, medications like non-steroidal anti-inflammatory drugs (NSAIDs) and exercise.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteoarthritis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Osteoarthritis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteoarthritis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteoarthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 13, 39, 27, 2, 5, 80, 23 and 2 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 2, 9 and 7 molecules, respectively.

Osteoarthritis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoarthritis (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Osteoarthritis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Osteoarthritis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Osteoarthritis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Osteoarthritis (Musculoskeletal Disorders)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Osteoarthritis (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Osteoarthritis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Osteoarthritis - Overview
Osteoarthritis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Osteoarthritis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Osteoarthritis - Companies Involved in Therapeutics Development
Osteoarthritis - Drug Profiles
Osteoarthritis - Dormant Projects
Osteoarthritis - Discontinued Products
Osteoarthritis - Product Development Milestones
Featured News & Press Releases
Apr 13, 2022: FDA grants Fast Track Designation for Paradigm Biopharmaceuticals phase III osteoarthritis program
Apr 08, 2022: TPX-100: OrthoTrophix presents new data suggesting joint bone shape as a possible surrogate marker for virtual joint replacement in knee osteoarthritis
Mar 17, 2022: Paradigm Biopharmaceuticals initiates a phase 3 clinical trial in knee osteoarthritis across the U.S
Mar 17, 2022: Paradigm has received regulatory and ethics approvals for the PARA_OA_002 clinical trial in the UK.
Mar 14, 2022: Medipost begins administration of knee osteoarthritis drug in P2 trial
Mar 03, 2022: 4P-Pharma and QuantHealth join forces to conduct AI-based in-Silico clinical trial simulations
Feb 17, 2022: Synartro granted European patent
Feb 08, 2022: Enveric Biosciences announces successful synthesis and filing of provisional patent for EV-104a - Cannabinoid + Celecoxib Conjugate
Jan 13, 2022: First subjects randomised dosed in PARA_0A_002 phase 3 study in Australia
Jan 12, 2022: Paradigm presentation at the 40th Annual J.P. Morgan Healthcare Conference
Dec 28, 2021: Kolon TissueGene resumes TG-C phase III studies in the U.S.
Dec 13, 2021: FDA approves XBiotechs IND in rheumatology
Dec 03, 2021: Kolon TissueGene to expand indications for TG-C
Nov 01, 2021: Two new studies demonstrate in vitro bioactivity potential of micronized dehydrated human amnion chorion membrane (mdHACM) to prevent pathological processes underlying osteoarthritis (OA) and tendinopathy
Sep 21, 2021: TPX-100: OrthoTrophix published a new research article demonstrating disease modification in knee osteoarthritis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Osteoarthritis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Osteoarthritis - Pipeline by 20MED Therapeutics BV, 2022
Osteoarthritis - Pipeline by 4P-Pharma SAS, 2022
Osteoarthritis - Pipeline by Abiogen Pharma SpA, 2022
Osteoarthritis - Pipeline by Achelios Therapeutics Inc, 2022
Osteoarthritis - Pipeline by Aclaris Therapeutics Inc, 2022
Osteoarthritis - Pipeline by Adare Pharma Solutions, 2022
Osteoarthritis - Pipeline by AfaSci Inc, 2022
Osteoarthritis - Pipeline by Ageless Biotech Inc, 2022
Osteoarthritis - Pipeline by Akaal Pharma Pty Ltd, 2022
Osteoarthritis - Pipeline by Akan Biosciences LLC, 2022
Osteoarthritis - Pipeline by AKL Research and Development Ltd, 2022
Osteoarthritis - Pipeline by Algomedix Inc, 2022
Osteoarthritis - Pipeline by Amgen Inc, 2022
Osteoarthritis - Pipeline by Amplicore Inc, 2022
Osteoarthritis - Pipeline by Amzell BV, 2022
Osteoarthritis - Pipeline by Aprogen Inc, 2022
Osteoarthritis - Pipeline by AskAt Inc, 2022
Osteoarthritis - Pipeline by Asta Pharmaceuticals Co Ltd, 2022
Osteoarthritis - Pipeline by Atlanthera, 2022
Osteoarthritis - Pipeline by Aurealis Pharma AG, 2022
Osteoarthritis - Pipeline by Axsome Therapeutics Inc, 2022
Osteoarthritis - Pipeline by Bioiberica SAU, 2022
Osteoarthritis - Pipeline by BioIntegrate Inc, 2022
Osteoarthritis - Pipeline by BioNet Pharma GmbH, 2022
Osteoarthritis - Pipeline by Bioorg3.14 LLC, 2022
Osteoarthritis - Pipeline by Biosplice Therapeutics Inc, 2022
Osteoarthritis - Pipeline by BioStem Technologies Inc, 2022
Osteoarthritis - Pipeline by Bioventus Inc, 2022
Osteoarthritis - Pipeline by BRIM Biotechnology Inc, 2022
Osteoarthritis - Pipeline by Buzzz Pharmaceuticals Ltd, 2022
Osteoarthritis - Pipeline by Caliway Biopharmaceutics Co Ltd, 2022
Osteoarthritis - Pipeline by CAR-T (Shanghai) Biotechnology Co Ltd, 2022
Osteoarthritis - Pipeline by Cartesian Therapeutics Inc, 2022
Osteoarthritis - Pipeline by CarthroniX Inc, 2022
Osteoarthritis - Pipeline by Cartilagen Inc, 2022
Osteoarthritis - Pipeline by Causeway Therapeutics Ltd, 2022
Osteoarthritis - Pipeline by Cellatoz Therapeutics Inc, 2022
Osteoarthritis - Pipeline by Cellics Therapeutics Inc, 2022
Osteoarthritis - Pipeline by CELLnLIFE Inc, 2022
Osteoarthritis - Pipeline by Cells for Cells SA, 2022
Osteoarthritis - Pipeline by CellTex Therapeutics Corp, 2022
Osteoarthritis - Pipeline by Cellular Biomedicine Group Inc, 2022
Osteoarthritis - Pipeline by Chondrogenix Ltd, 2022
Osteoarthritis - Pipeline by Cmxtwenty, 2022
Osteoarthritis - Pipeline by Cocoon Biotech, Inc., 2022
Osteoarthritis - Pipeline by Corestem Inc, 2022
Osteoarthritis - Pipeline by CrystalGenomics Inc, 2022
Osteoarthritis - Pipeline by Cynata Therapeutics Ltd, 2022
Osteoarthritis - Pipeline by Cytonics Corp, 2022
Osteoarthritis - Pipeline by Cytopeutics Pte Ltd, 2022
Osteoarthritis - Pipeline by Daewoong Pharmaceutical Co Ltd, 2022
Osteoarthritis - Pipeline by Dianomi Therapeutics Inc, 2022
Osteoarthritis - Pipeline by DNX Biopharmaceuticals Inc, 2022
Osteoarthritis - Pipeline by Dongkook Pharmaceutical Co Ltd, 2022
Osteoarthritis - Pipeline by Eli Lilly and Co, 2022
Osteoarthritis - Pipeline by Ensol Biosciences Inc, 2022
Osteoarthritis - Pipeline by Enveric Biosciences Inc, 2022
Osteoarthritis - Pipeline by Epione Therapeutics BV, 2022
Osteoarthritis - Pipeline by Eternity Bioscience Inc, 2022
Osteoarthritis - Pipeline by Evgen Pharma Plc, 2022
Osteoarthritis - Pipeline by Exostemtech Co Ltd, 2022
Osteoarthritis - Pipeline by Flexion Therapeutics Inc, 2022
Osteoarthritis - Pipeline by Genascence Corp, 2022
Osteoarthritis - Pipeline by Genequine Biotherapeutics GmbH, 2022
Osteoarthritis - Pipeline by General Regeneratives Shanghai Ltd, 2022
Osteoarthritis - Pipeline by General Therapeutics Inc, 2022
Osteoarthritis - Pipeline by GlaxoSmithKline Plc, 2022
Osteoarthritis - Pipeline by GPN Therapeutics Inc, 2022
Osteoarthritis - Pipeline by Guangzhou Saliai Stemcell Science and Technology Co Ltd, 2022
Osteoarthritis - Pipeline by Gwoxi Stem Cell Applied Technology Co Ltd, 2022
Osteoarthritis - Pipeline by Haplnscience Inc, 2022
Osteoarthritis - Pipeline by Hisamitsu Pharmaceutical Co Inc, 2022
Osteoarthritis - Pipeline by Histogen Inc, 2022
Osteoarthritis - Pipeline by Hope Biosciences LLC, 2022
Osteoarthritis - Pipeline by Huaxia Source Cell Engineering Group Co Ltd, 2022
Osteoarthritis - Pipeline by iCELL Biotechnology Co Ltd, 2022
Osteoarthritis - Pipeline by ICM Co Ltd, 2022
Osteoarthritis - Pipeline by Immetas Therapeutics Inc, 2022
Osteoarthritis - Pipeline by ImmuneCyte Inc, 2022
Osteoarthritis - Pipeline by ImmunoForge Co Ltd, 2022
Osteoarthritis - Pipeline by Inception Therapeutics Inc, 2022
Osteoarthritis - Pipeline by International Stem Cell Corp, 2022
Osteoarthritis - Pipeline by Johnson & Johnson, 2022
Osteoarthritis - Pipeline by Juniper Biologics Pte Ltd, 2022
Osteoarthritis - Pipeline by Juvena Therapeutics Inc, 2022
Osteoarthritis - Pipeline by Kaken Pharmaceutical Co Ltd, 2022
Osteoarthritis - Pipeline by Kangstem Biotech Co Ltd, 2022
Osteoarthritis - Pipeline by Kolon TissueGene Inc, 2022
Osteoarthritis - Pipeline by Kukje Pharmaceutical Industry Co Ltd, 2022
Osteoarthritis - Pipeline by Levolta Pharmaceuticals Inc, 2022
Osteoarthritis - Pipeline by LG Chem Ltd, 2022
Osteoarthritis - Pipeline by Likarda LLC, 2022
Osteoarthritis - Pipeline by Link Biologics Ltd, 2022
Osteoarthritis - Pipeline by Link Health Group, 2022
Osteoarthritis - Pipeline by Lubris Biopharma, 2022
Osteoarthritis - Pipeline by Luye Pharma Group Ltd, 2022
Osteoarthritis - Pipeline by Magellan Biologicals Pty Ltd, 2022
Osteoarthritis - Pipeline by MDimune Inc, 2022
Osteoarthritis - Pipeline by Mecox Cure Med Co Ltd, 2022
Osteoarthritis - Pipeline by Medicrinia Co Ltd, 2022
Osteoarthritis - Pipeline by MediPost Co Ltd, 2022
Osteoarthritis - Pipeline by Medivir AB, 2022
Osteoarthritis - Pipeline by MeiraGTx Holdings Plc, 2022
Osteoarthritis - Pipeline by Meluha Life Sciences Sdn Bhd, 2022
Osteoarthritis - Pipeline by Merck KGaA, 2022
Osteoarthritis - Pipeline by Meridigen Biotech Co Ltd, 2022
Osteoarthritis - Pipeline by Mesoblast Ltd, 2022
Osteoarthritis - Pipeline by MetrioPharm AG, 2022
Osteoarthritis - Pipeline by MiMedx Group Inc, 2022
Osteoarthritis - Pipeline by Mor Research Applications Ltd, 2022
Osteoarthritis - Pipeline by Nanode Therapeutics Inc, 2022
Osteoarthritis - Pipeline by NeuroBo Pharmaceuticals Inc, 2022
Osteoarthritis - Pipeline by New York R&D Center for Translational Medicine and Therapeutics Inc, 2022
Osteoarthritis - Pipeline by Nexbiome Therapeutics, 2022
Osteoarthritis - Pipeline by Nordic Bioscience AS, 2022
Osteoarthritis - Pipeline by Novartis AG, 2022
Osteoarthritis - Pipeline by Novo Nordisk AS, 2022
Osteoarthritis - Pipeline by Orbsen Therapeutics Ltd, 2022
Osteoarthritis - Pipeline by Organicell Regenerative Medicine Inc, 2022
Osteoarthritis - Pipeline by Organogenesis Holdings Inc, 2022
Osteoarthritis - Pipeline by OrthoTrophix Inc, 2022
Osteoarthritis - Pipeline by Oxacell AG, 2022
Osteoarthritis - Pipeline by Paradigm Biopharmaceuticals Ltd, 2022
Osteoarthritis - Pipeline by Paras Biopharmaceuticals Finland Oy, 2022
Osteoarthritis - Pipeline by Parnia Stem Cell Knowledge-Based Co, 2022
Osteoarthritis - Pipeline by Peptinov SAS, 2022
Osteoarthritis - Pipeline by Personalized Stem Cells Inc, 2022
Osteoarthritis - Pipeline by PersonGen BioTherapeutics (Suzhou) Co Ltd, 2022
Osteoarthritis - Pipeline by Pfizer Inc, 2022
Osteoarthritis - Pipeline by PhytoHealth Corp, 2022
Osteoarthritis - Pipeline by Plakous Therapeutics Inc, 2022
Osteoarthritis - Pipeline by PlateletBio, 2022
Osteoarthritis - Pipeline by PMG PHARM Co Ltd, 2022
Osteoarthritis - Pipeline by PrimeGen Global Inc, 2022
Osteoarthritis - Pipeline by PrimRNA Inc, 2022
Osteoarthritis - Pipeline by Progenitor Therapeutics Ltd, 2022
Osteoarthritis - Pipeline by ProteoThera Inc, 2022
Osteoarthritis - Pipeline by Regeneus Ltd, 2022
Osteoarthritis - Pipeline by Regenosine Inc, 2022
Osteoarthritis - Pipeline by Regulaxis SAS, 2022
Osteoarthritis - Pipeline by Remedium Bio Inc, 2022
Osteoarthritis - Pipeline by ReqMed Co Ltd, 2022
Osteoarthritis - Pipeline by Ribomic Inc, 2022
Osteoarthritis - Pipeline by Rottapharm Biotech Srl, 2022
Osteoarthritis - Pipeline by Runjia (Suzhou) Pharmaceutical Technology Co Ltd, 2022
Osteoarthritis - Pipeline by Sclnow Biotechnology Co Ltd, 2022
Osteoarthritis - Pipeline by Seikagaku Corp, 2022
Osteoarthritis - Pipeline by Serene LLC, 2022
Osteoarthritis - Pipeline by Shandong Boan Biotechnology Co Ltd, 2022
Osteoarthritis - Pipeline by Shionogi & Co Ltd, 2022
Osteoarthritis - Pipeline by Simcere Pharmaceutical Group Ltd, 2022
Osteoarthritis - Pipeline by SL Bigen Co Ltd, 2022
Osteoarthritis - Pipeline by Steminent Biotherapeutics Inc, 2022
Osteoarthritis - Pipeline by Stempeutics Research Pvt Ltd, 2022
Osteoarthritis - Pipeline by Synartro AB, 2022
Osteoarthritis - Pipeline by Synerkine Pharma BV, 2022
Osteoarthritis - Pipeline by Synokem Pharmaceuticals Ltd, 2022
Osteoarthritis - Pipeline by Taiwan Bio Therapeutics Co Ltd, 2022
Osteoarthritis - Pipeline by Techfields Pharma Co Ltd, 2022
Osteoarthritis - Pipeline by TheraBioPharma Inc, 2022
Osteoarthritis - Pipeline by Traverse Biosciences Inc, 2022
Osteoarthritis - Pipeline by Tremeau Pharmaceuticals Inc, 2022
Osteoarthritis - Pipeline by Trialspark Inc, 2022
Osteoarthritis - Pipeline by Turn Biotechnologies Inc, 2022
Osteoarthritis - Pipeline by Unicocell Biomed Co Ltd, 2022
Osteoarthritis - Pipeline by Vitro Diagnostics Inc, 2022
Osteoarthritis - Pipeline by WEX Pharmaceuticals Inc, 2022
Osteoarthritis - Pipeline by WNT Scientific LLC, 2022
Osteoarthritis - Pipeline by Xalud Therapeutics Inc, 2022
Osteoarthritis - Pipeline by Xintela AB, 2022
Osteoarthritis - Pipeline by Yooyoung Pharm Co Ltd, 2022
Osteoarthritis - Pipeline by Zhejiang Yatai Pharmaceutical Co Ltd, 2022
Osteoarthritis - Pipeline by Zimmer Biomet Holdings Inc, 2022
Osteoarthritis - Dormant Projects, 2022
Osteoarthritis - Discontinued Products, 2022

List of Figures
Number of Products under Development for Osteoarthritis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

  • Not Sure / Need Reassuring
    • Confirm Content
      • Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:

        Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.

        Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.

        Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.

    • Sample Pages
      • With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.

        It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.

        To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Check for Alternatives
      • Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.

        To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.

  • Prices / Formats / Delivery
    • Prices
      • All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.

        Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Discounts
      • As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.

        Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.

        To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Available Currencies
      • Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.

        Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.

        To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.

    • Licenses
      • License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Global Site License
      • The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.

        It is important to note that this may exclude Parent Companies or Subsidiaries.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Formats
      • The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.

        If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.

    • Delivery
      • Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.

        Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.

        If a delay in delivery is expected you will be informed about it immediately.

    • Shipping Charges
      • As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.

        If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.

  • Ordering
    • By Credit Card
      • We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.

        Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.

        For more information on PayU please visit: https://www.payu.pl/en/about-us

    • By Money Transfer
      • If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.

        With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.

  • Security
    • Website security
      • We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.

        Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.

    • Credit Card Security
      • We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.

        PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.

PLEASE SELECT LICENSE
  • $2500.00
  • $5000.00
  • $7500.00
  • ADD TO BASKET
  • BUY NOW